PolyMedix to Review Full Results From Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
April 20, 2012 16:05 ET
|
PolyMedix, Inc.
RADNOR, Pa., April 20, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
PolyMedix Restructures Its Debt and Secures $12 Million Credit Facility
April 10, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., April 10, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions,...
PolyMedix's PMX-30063 First in Class Defensin-Mimetic Antibiotic Demonstrates Activity Against Drug-Resistant Bacterial Pathogens
April 02, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., April 2, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions,...
PolyMedix to Present at the Roth 24th Annual Growth Stock Conference
March 05, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., March 5, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, will be...
PolyMedix to Present at the Cowen 32nd Annual Health Care Conference
February 28, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Feb. 28, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions,...
PolyMedix to Present at the 14th Annual BIO CEO and Investor Conference
February 07, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Feb. 7, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, will be...
PolyMedix Defensin-Mimetic Antimicrobial Compounds Show Activity Against Oral Candida Fungus and Malaria
January 20, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Jan. 20, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions,...
PolyMedix Completes Enrollment in Phase 2 Trial With PMX-30063 Defensin-Mimetic Antibiotic
January 04, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Jan. 4, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced...
PolyMedix Announces Encouraging Interim Results From Multinational Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
December 07, 2011 07:00 ET
|
PolyMedix, Inc.
Efficacy and Safety Demonstrated in All Evaluated Dose Groups
First Clinical Study with New Class of Antibiotic in Patients with S. aureus ABSSSI Infections
Conference Call Today at 9:00 am...
PolyMedix to Review Interim Results From Multinational Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
December 06, 2011 16:30 ET
|
PolyMedix, Inc.
RADNOR, Pa., Dec. 6, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTC BB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and...